Why Sanofi Stock Could Fall Next: Bearish Drivers Ahead

01. Historical Context

Why the current setup could evolve into a deeper drawdown

The bearish setup for Sanofi starts from a different place than for expensive growth stocks. At EUR 74.04 on May 15, 2026, the stock already sits near its 52-week low and around 11x forward earnings. That means downside needs a real thesis change, not just a valuation reset.

The areas to watch are obvious. Dupixent contributed EUR 4.2 billion in Q1 2026, up 30.8%; launches added EUR 1.2 billion, up 49.6%; vaccines were EUR 1.3 billion, up 2.1%. Those are strong numbers, but they also show how dependent the current story still is on one franchise and a small group of launches.

When low-multiple pharma stocks fall, it is usually because investors stop believing that the next generation of products can keep the earnings base from flattening. That is the actual bear case here.

Bearish setup for Sanofi using current verified datapoints — Downside framework anchored to the current price, recent operating data, and today's valuation setup.

Sanofi framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were EUR 10.509 billion, up 13.6% at constant exchange rates, while business EPS was EUR 1.88, up 14.0% at CER.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Sanofi on about 12.9x trailing 2025 earnings, 10.9x 2026 estimated earnings, and 10.1x 2027 estimated earnings. Consensus EPS on MarketScreener was EUR 6.852 for 2026 and EUR 7.372 for 2027, implying about 7.6% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2030	Structural compounding	10-year price range EUR 44.62 to EUR 94.70; 10-year CAGR 4.1%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five bearish forces that could pull the stock lower

The first bearish force would be a slower Dupixent trajectory. Because the franchise is so large, even a modest slowdown can have an outsized valuation effect.

The second bearish force is launch slippage. A lot of the upside argument rests on newer products continuing to scale. If that stalls, the stock's cheapness stops looking like opportunity and starts looking deserved.

The third bearish force is FX. Management itself warned that 2026 FX could subtract around 2% from sales and 3% from business EPS at January rates, which can worsen the optics in a skeptical tape.

The fourth bearish force is sector breadth. FactSet still shows healthcare lagging on earnings breadth, which means the market is not in a forgiving mood.

The fifth bearish force is policy pressure. Healthcare can remain undervalued for long periods when reimbursement or pricing concerns dominate the narrative.

Current factor scorecard for Sanofi

Factor	Current Assessment	Bias	Why it matters now
Dupixent sensitivity	Large share of current sales and profits	Neutral to Bearish	The bigger the franchise, the bigger the downside if growth slows.
Launch dependence	Launches up 49.6% in Q1 2026	Neutral	Great now, but must stay strong.
FX pressure	About negative 2% sales and negative 3% EPS guide impact at January rates	Bearish	Reported prints can look weaker than operations.
Sector backdrop	Healthcare still a weak breadth sector in FactSet data	Bearish	The market is not rewarding every pharma stock equally.
Valuation	Low forward multiple	Bullish for downside protection	A cheap multiple limits but does not remove risk.

03. Countercase

What could invalidate the bearish thesis

The bear case is real, but it is not symmetrical with the bull case. Sanofi already trades well below analyst targets and on a low multiple, so downside usually requires a visible deterioration in the operating story.

The clearest bearish trigger would be a meaningful slowdown in Dupixent combined with softer launch growth. That would challenge the market's assumption that 2026-2027 earnings can keep stepping higher.

A second bearish trigger would be negative estimate revisions. Because the stock is already cheap, price damage would likely come from earnings cuts, not just sentiment.

Current constraints on the bear case

Risk	Latest datapoint	Current assessment	Bias
Estimate cuts	Would be the cleanest way to break the low-multiple support	Not visible yet	Neutral
Franchise slowdown	Would need a clear Dupixent or launch miss	Key trigger	Bearish if it appears
Sector weakness	Already present in breadth data	Known headwind	Neutral
Valuation floor	Around 10x-11x forward earnings	Partial cushion	Bullish offset

04. Institutional Lens

What named research says about the downside case

Institutional context does not support a maximalist bear case right now. J.P. Morgan says healthcare is cheap relative to the broader market, and MarketScreener still shows an Outperform consensus with a target range above the current share price.

The more realistic institutional bear lens comes from FactSet and the IMF. FactSet says healthcare breadth is still soft, while the IMF says downside macro risks dominate the global outlook. That combination can keep low-multiple healthcare stocks from rerating even when they are not fundamentally broken.

So the bearish question is not whether Sanofi is overpriced. It is whether the earnings bridge the market expects is actually sturdy enough.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	MarketScreener listed 24 analysts on May 7, 2026 with an Outperform consensus, average target EUR 97.10, low target EUR 82.00, and high target EUR 112.00.	Analysts still see upside because the stock is screening at a low-teens trailing P/E and about 11x forward earnings.	That institutional setup matters because Sanofi does not need an aggressive multiple to outperform if launches keep delivering.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

How to define the downside case with measurable triggers

For bearish positioning, the most important rule is to demand evidence. Sanofi is not the kind of stock where a broad-market wobble automatically creates a durable short thesis.

Investors should focus on whether 2027 EPS estimates begin to fall, whether launches start missing, and whether the stock loses the EUR 71-EUR 72 area that marks the recent 52-week low zone.

Bearish scenario map for Sanofi

Scenario	Probability	Target range	Trigger	When to review
Bearish follow-through	30%	EUR 62 to EUR 70	Launches slow, Dupixent growth cools, and EPS estimates are cut.	Review after Q2 2026 and each analyst revision cycle.
Sideways de-rating	40%	EUR 70 to EUR 78	The stock stays cheap but does not rerate because sentiment remains cautious.	Review after FY 2026.
Bear case fails	30%	Above EUR 78	Guidance holds and launches stay strong enough to block the de-rating thesis.	Review immediately after each clean quarterly print.